ClinicalTrials.gg
Not yet recruitingNCT07846020PATUpdated Sep 29, 2026

Mechanistic Evaluation of Polypharmacy Effects for Pain

A Phase 1/2 interventional study of Within-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin) in Chronic Lower Back Pain (CLBP), sponsored by University of Maryland, Baltimore. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by University of Maryland, Baltimore · Phase 1/2, Interventional, and Treatment

How we know

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 712 studies in Low Back Pain with a site in United States — 100 open to participants now, 126 under way, 3 of them phase 3. Low Back Pain · United States.

Planned enrollment
245th of 623
110 · median 79
Started
2027
with 3 others
Phase 1/2
10 of 712
1 open now
Primary completion
2032-01
later than 123 of 125 live
Registered
707th of 712
by date

Among the 712 studies in Low Back Pain with a site in United States, this one is the 245th largest by planned enrollment of the 623 interventional ones that give a count, is one of 4 that started in 2027, is one of 10 in phase 1/2, reaches primary completion later than 123 of the 125 other live ones, and was the 707th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

100 of the 712 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:

95 more — sign in →

All 100 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 712 studies in Low Back Pain with a site in United States, or all of them as a file.
02

Study summary

This is a single-group, within-subject, double-blind, double-dummy, placebo-controlled study evaluating whether gabapentin (Neurontin) changes the analgesic, safety, and subjective effects of the opioid hydromorphone (Dilaudid) when the two are combined.

Read the detailed description

This is a human laboratory systematic examination of whether adding the FDA-approved gabapentin (Neurontin; oral) to the FDA-approved opioid hydromorphone (Dilaudid; oral) will change the experience of hydromorphone as rated by laboratory measures of pain, subjective reports of drug effects, and cognitive performance. Subjects are healthy individuals with chronic lower back pain and no history of substance use disorder. Study subjects and staff are blinded to the study drugs and the class of drugs under investigation and are informed that subjects may receive opioids, stimulants, gabapentinoids, cannabinoids, benzodiazepines, over the counter medications, and/or placebo. Sessions last up to 8-hours in an outpatient setting. Primary outcomes are collected from participants prior to dosing and at several hour periods post-dosing.

03

Conditions studied

  • Chronic Lower Back Pain (CLBP)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-65 years old
  • Lifetime history of opioid use
  • Medically cleared to take study medications
  • Chronic Lower Back Pain
  • Agree to use effective form of throughout enrollment

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Have evidence of physical dependence on or current use of any central nervous system depressants including but not limited to alcohol, benzodiazepines, opioids, gabapentinoids, or barbiturates
  • Past 30-day use of certain pain medications
  • Evidence of past 7-day nonmedical drug use
  • Known hypersensitvity, allergy to, or history of adverse reactions to study medications
  • Are currently taking a medication or have a condition that is with either study medication
  • Have evidence of current or past significant medical/psychiatric illness
  • Have a history of cardiac arrhythmias or vasospastic disease
  • Have evidence of renal or hepatic impairment
  • Current suicidal ideation or behavior, or a history of a suicide attempt within the past 2 years
  • Have any condition that may increases the risk for respiratory depression
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
110 participants (estimated)

Study arms

  • Placebo comparator
    Placebo hydromorphone, Placebo gabapentin

    0mg oral hydromorphone, 0mg oral gabapentin

    Drug: Within-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin)

  • Experimental
    Active hydromorphone, Low dose gabapentin

    4mg oral hydromorphone, 300mg oral gabapentin

    Drug: Within-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin)

  • Experimental
    Active hydromorphone, High dose gabapentin

    4mg oral hydromorphone, 900mg oral gabapentin

    Drug: Within-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin)

  • Active comparator
    Placebo hydromorphone, Low dose gabapentin

    0mg oral hydromorphone, 300mg oral gabapentin

    Drug: Within-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin)

  • Active comparator
    Placebo hydromorphone, High dose gabapentin

    0mg oral hydromorphone, 900mg oral gabapentin

    Drug: Within-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin)

  • Active comparator
    Active hydromorphone, placebo gabapentin

    4mg oral hydromorphone, 0mg gabapentin

    Drug: Within-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin)

Interventions

  • DrugWithin-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin)

    Within-subject double-blind, double-dummy, study design wherein all participants received all drug combinations (Placebo + Placebo, Hydromorphone + Placebo, Low Dose Gabapentin + Placebo, High Dose Gabapentin + Placebo, Low Dose Gabapentin + Hydromorphone, High Dose Gabapentin + Hydromorphone) in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.

06

What researchers measure

Primary outcomes

  1. Peak change from baseline Drug Effect

    Peak self-reported "Drug Effect" on a visual analogue scale (0-100) minus baseline ratings of self-reported "Drug Effect" on a visual anaogue scale (0-100)

    Time frame: 8 hour study sessions

  2. Peak change from baseline Good Effect

    Peak self-reported "Good Effect" on a visual analogue scale (0-100) minus baseline ratings of self-reported "Good Effect" on a visual anaogue scale (0-100), where lower scores indicate no effect and greater scores indicate maximum effect.

    Time frame: Baseline (0.5 hours before drug administration) and 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, and 8 hours after drug administration

  3. Peak Cold Pressor Test Tolerance change from baseline score

    Peak Cold Pressor Test Tolerance Score minus baseline Peak Cold Pressor Test Tolerance score. Outcome ranges from 0-60 seconds, 0 indicating low analgesic effect and 60 indicating high analgesic effects.

    Time frame: Baseline (0.5 hours before drug administration) and 4 and 6 hours after study drug administration

  4. Peak Cold Pressor Test Threshold change from baseline score

    Peak Cold Pressor Test Threshold Score minus baseline Peak Cold Pressor Test Threshold score. Outcome ranges from 0-60 seconds, 0 indicating low analgesic effect and 60 indicating high analgesic effects.

    Time frame: Baseline (0.5 hours before drug administration) and 4 and 6 hours after study drug administration

  5. Peak Heat Pain with Capsaicin Threshold change from baseline score

    Peak Heat Pain with Capsaicin Threshold score minus baseline Peak Heat Pain with Capsaicin Threshold score. Outcome ranges from 0-100, 0 indicating no pain and 100 indicating extreme pain.

    Time frame: Baseline (0.5 hours before drug administration) and 4 and 6 hours after study drug administration

  6. Peak Heat Pain with Capsaicin Tolerance Change from Baseline Score

    Peak Heat Pain with Capsaicin Tolerance score minus baseline Peak Heat Pain with Capsaicin Tolerance score. Outcome ranges from 0-100, 0 indicating no pain and 100 indicating extreme pain.

    Time frame: Baseline (0.5 hours before drug administration) and 4 and 6 hours after study drug administration

  7. Peak change from baseline Bad Effect

    Peak self-reported "Bad Effect" on a visual analogue scale (0-100) minus baseline ratings of self-reported "Bad Effect" on a visual anaogue scale (0-100) where lower scores indicate no effect and greater scores indicate maximum effect.

    Time frame: Baseline (0.5 hours before drug administration) and 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, and 8 hours after drug administration

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Jan 2032, 60 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2026
First posted
Sep 29, 2026
StartEst.
Jan 15, 2027
Primary completionEst.
Jan 15, 2032
CompletionEst.
Apr 1, 2032
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07846020
Responsible party
Cecilia Bergeria (Associate Professor, University of Maryland, Baltimore) — Principal investigator
First posted
Sep 29, 2026
Start date
Jan 15, 2027 (estimated)
Primary completion
Jan 15, 2032 (estimated)
Completion
Apr 1, 2032 (estimated)
Last update
Sep 29, 2026

Study contacts

Sarah Dowell
Contact
sdowell@som.umaryland.edu
667-351-5088

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion